Mary Claire Maxwell
University of Texas Southwestern Medical Center
4 Papers
7 Citations
Mary Claire Maxwell is an academic researcher from University of Texas Southwestern Medical Center. The author has contributed to research in topics: Cancer & Internal medicine. The author has an hindex of 1, co-authored 1 publications.
Chat about Author
Papers
A Propensity Score Analysis of Chemotherapy Use in Patients With Resectable Gallbladder Cancer
Muhammet Ozer,Suleyman Yasin Goksu,Nina N. Sanford,Matthew R. Porembka,Hajra Khurshid,Chul Ahn,Mary Claire Maxwell,Muhammad Shaalan Beg,Syed Mohammad Ali Kazmi +8 more
TL;DR: In this article , the authors examined the use and outcomes associated with neoadjuvant and adjuvant chemotherapy vs surgery alone in patients with resectable gallbladder cancer.
23
Racial Disparities in Time to Treatment Initiation and Outcomes for Early Stage Anal Squamous Cell Carcinoma.
Suleyman Yasin Goksu,Muhammet Ozer,Syed Mohammad Ali Kazmi,Todd A. Aguilera,Chul Ahn,David Hsiehchen,Aravind Sanjeevaiah,Mary Claire Maxwell,Muhammad Shaalan Beg,Nina N. Sanford +9 more
TL;DR: Black patients had a longer time to treatment initiation and worse OS as compared with White patients with early stage ASCC treated with chemoradiation, and further research is needed to better elucidate the etiologies of these disparities.
10
P018 TROPION-Breast03: Datopotamab deruxtecan (Dato-DXd) ± durvalumab vs investigator’s choice of therapy (ICT) for triple-negative breast cancer (TNBC) with residual disease following neoadjuvant therapy
Aditya Bardia,Lajos Pusztai,KS Albain,Kevin Kalinsky,D. Hershman,W. Barlow,Eriko Tokunaga,Eva Ciruelos,Delphine Loirat,Claudine Isaacs,Laura Testa,Hannah Dry,Robert Kozarski,Mary Claire Maxwell,Nadia Harbeck,Priyanka Sharma +15 more
The phosphatidylserine targeting antibody bavituximab plus pembrolizumab in unresectable hepatocellular carcinoma: a phase 2 trial
David Hsiehchen,M. S. Beg,Radhika Kainthla,J. Lohrey,Syed M Kazmi,Leticia Khosama,Mary Claire Maxwell,Heather Kline,Courtney Katz,Asim Hassan,Naoto Kubota,Ellen Siglinsky,Anil K Pillai,Hagop Youssoufian,Colleen Mockbee,Kerry Culm,Mark Uhlik,Laura Benjamin,Rolf A Brekken,Chul Ahn,Amit G. Singal,Hao Zhu,Yujin Hoshida,Adam C. Yopp +23 more
TL;DR: A phase 2 trial combining bavituximab (phosphatidylserine targeting antibody) with pembrolizumab (anti-PD-1) in unresectable hepatocellular carcinoma achieved a 32.1% confirmed response rate and 6.3-month median progression-free survival with manageable toxicity.